The story of Sildenafil presents a complex picture for investors. While the initial release generated substantial returns, the lapse of its patent opened the door to off-brand alternatives, dramatically reducing sales. This poses a specific risk for drug manufacturers depending on comparable blockbuster medications, suggesting that a unquestioning

The history of Viagra, and its parent company copyright, presents a challenging case study for investors. Initially a blockbuster drug, generating billions in revenue , its intellectual property lapse created a wave of knock-off medications, significantly eroding its market share . While certain pharmaceutical companies may try to capitalize on sim